[{"address1": "217 Queen Street West", "address2": "Suite 301", "city": "Toronto", "state": "ON", "zip": "M5V 0R2", "country": "Canada", "website": "https://awaknlifesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S\u0096ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders; and with the University of Nottingham focusing on evaluating the company's lead aminoindane series and its potential to enhance social cognition and pro-social behaviors. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Mr. George  Scorsis", "age": 46, "title": "Co-founder & Chairman of the Board", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Tennyson", "title": "Co-founder, President, CEO & Director", "fiscalYear": 2023, "totalPay": 178448, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan James Held C.A., CPA, CA", "age": 37, "title": "Co-founder, CFO, Chief Business Officer & Secretary", "yearBorn": 1986, "fiscalYear": 2023, "totalPay": 111533, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D.", "title": "Chair of Pre-Clinical & Clinical Advisory Board and Chief Research Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.075, "open": 0.075, "dayLow": 0.075, "dayHigh": 0.075, "regularMarketPreviousClose": 0.075, "regularMarketOpen": 0.075, "regularMarketDayLow": 0.075, "regularMarketDayHigh": 0.075, "beta": 2.66, "forwardPE": -0.30833334, "volume": 4250, "regularMarketVolume": 4250, "averageVolume": 19784, "averageVolume10days": 38450, "averageDailyVolume10Day": 38450, "bid": 0.07, "ask": 0.08, "marketCap": 3083032, "fiftyTwoWeekLow": 0.04872, "fiftyTwoWeekHigh": 0.1877, "priceToSalesTrailing12Months": 37.401367, "fiftyDayAverage": 0.082265, "twoHundredDayAverage": 0.09412585, "currency": "USD", "enterpriseValue": 2370329, "floatShares": 34944109, "sharesOutstanding": 41662600, "heldPercentInsiders": 0.078260005, "heldPercentInstitutions": 0.057690002, "impliedSharesOutstanding": 42581000, "bookValue": -0.038, "lastFiscalYearEnd": 1706659200, "nextFiscalYearEnd": 1738281600, "mostRecentQuarter": 1722384000, "netIncomeToCommon": -2868462, "trailingEps": -0.06, "forwardEps": -0.24, "enterpriseToRevenue": 28.755, "enterpriseToEbitda": -0.91, "52WeekChange": -0.27236974, "SandP52WeekChange": 0.31754446, "exchange": "OQB", "quoteType": "EQUITY", "symbol": "AWKNF", "underlyingSymbol": "AWKNF", "shortName": "Awakn Life Sciences Corp.", "longName": "Awakn Life Sciences Corp.", "firstTradeDateEpochUtc": 1627997400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "595fd0b1-2e29-3fed-b382-0b786bf6dbf2", "messageBoardId": "finmb_673256170", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.074, "recommendationKey": "none", "totalCash": 712705, "totalCashPerShare": 0.017, "ebitda": -2603439, "quickRatio": 0.304, "currentRatio": 0.35, "totalRevenue": 82431, "revenuePerShare": 0.002, "returnOnAssets": -1.82752, "freeCashflow": -686468, "operatingCashflow": 2191688, "revenueGrowth": -0.553, "grossMargins": 1.0, "operatingMargins": -52.97299, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2024-12-07"}]